The therapeutic effects of lacosamide on epilepsy-associated comorbidities

被引:3
作者
He, Zihua [1 ]
Li, Jinmei [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Peoples R China
来源
FRONTIERS IN NEUROLOGY | 2023年 / 14卷
基金
中国国家自然科学基金;
关键词
epilepsy; lacosamide; anti-seizure medications; epilepsy comorbidities; psychiatric disorders; PARTIAL-ONSET SEIZURES; GATED SODIUM-CHANNELS; QUALITY-OF-LIFE; ADJUNCTIVE LACOSAMIDE; DOUBLE-BLIND; OPEN-LABEL; ANTIEPILEPTIC DRUGS; ELDERLY-PATIENTS; REFRACTORY EPILEPSY; CHILDHOOD EPILEPSY;
D O I
10.3389/fneur.2023.1063703
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Epilepsy is a chronic neurological disorder associated with severe social and psychological effects, and most epilepsy patients often report at least one comorbidity. Accumulating evidence have suggested that lacosamide, a new generation of anti-seizure medications, may exhibit efficacy in the management of both epilepsy and its related comorbidities. Therefore, this narrative review aimed to elucidate the recent advancements regarding the therapeutic role of lacosamide in epilepsy-associated comorbidities. The possible pathophysiological mechanisms between epilepsy and epilepsy-associated comorbidities have been also partially described. Whether lacosamide improves cognitive and behavioral functions in patients with epilepsy has not been conclusively established. Some studies support that lacosamide may alleviate anxiety and depression in epilepsy patients. In addition, lacosamide has been found to be safe and effective in the treatment of epilepsy in people with intellectual disabilities, epilepsy of cerebrovascular etiology, and epilepsy associated with brain tumors. Moreover, lacosamide treatment has demonstrated fewer side effects on other systems. Hence, future larger and higher quality clinical studies are needed to further explore both the safety and efficacy of lacosamide in the treatment of epilepsy-associated comorbidities.
引用
收藏
页数:9
相关论文
共 110 条
  • [1] Comorbidity and Childhood Epilepsy: A Nationwide Registry Study
    Aaberg, Kari Modalsli
    Bakken, Inger Johanne
    Lossius, Morten I.
    Soraas, Camilla Lund
    Haberg, Siri Eldevik
    Stoltenberg, Camilla
    Suren, Pal
    Chin, Richard
    [J]. PEDIATRICS, 2016, 138 (03)
  • [2] Revisiting the role of neurotransmitters in epilepsy: An updated review
    Akyuz, Enes
    Polat, Ayse Kristina
    Eroglu, Ece
    Kullu, Irem
    Angelopoulou, Efthalia
    Paudel, Yam Nath
    [J]. LIFE SCIENCES, 2021, 265
  • [3] Obesity and overweight as CAE comorbidities and differential drug response modifiers
    Arya, Ravindra
    Gillespie, Catherine W.
    Cnaan, Avital
    Devarajan, Mahima
    Clark, Peggy
    Shinnar, Shlomo
    Vinks, Alexander A.
    Mizuno, Kana
    Glauser, Tracy A.
    [J]. NEUROLOGY, 2016, 86 (17) : 1613 - 1621
  • [4] Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission
    Auvin, Stephane
    Wirrell, Elaine
    Donald, Kirsten A.
    Berl, Madison
    Hartmann, Hans
    Valente, Kette D.
    Van Bogaert, Patrick
    Cross, J. Helen
    Osawa, Makiko
    Kanemura, Hideaki
    Aihara, Masao
    Guerreiro, Marilisa M.
    Samia, Pauline
    Vinayan, Kollencheri Puthenveettil
    Smith, Mary Lou
    Carmant, Lionel
    Kerr, Michael
    Hermann, Bruce
    Dunn, David
    Wilmshurst, Jo M.
    [J]. EPILEPSIA, 2018, 59 (10) : 1867 - 1880
  • [5] Glutamatergic Mechanisms Associated with Seizures and Epilepsy
    Barker-Haliski, Melissa
    White, H. Steve
    [J]. COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2015, 5 (08): : 1 - 15
  • [6] Lacosamide and sodium channel-blocking antiepileptic drug cross-titration against levetiracetam background therapy
    Baulac, M.
    Byrnes, W.
    Williams, P.
    Borghs, S.
    Webster, E.
    De Backer, M.
    Dedeken, P.
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2017, 135 (04): : 434 - 441
  • [7] Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial
    Baulac, Michel
    Rosenow, Felix
    Toledo, Manuel
    Terada, Kiyohito
    Li, Ting
    De Backer, Marc
    Werhahn, Konrad
    Brock, Melissa
    [J]. LANCET NEUROLOGY, 2017, 16 (01) : 43 - 54
  • [8] Intravenous lacosamide as treatment option in post-stroke non convulsive status epilepticus in the elderly: A proof-of-concept, observational study
    Belcastro, Vincenzo
    Vidale, Simone
    Pierguidi, Laura
    Sironi, Luigi
    Tancredi, Lucia
    Striano, Pasquale
    Taborelli, Angelo
    Arnaboldi, Marco
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2013, 22 (10): : 905 - 907
  • [9] Long-term safety and tolerability of lacosamide monotherapy in patients with epilepsy: Results from a multicenter, open-label trial
    Ben-Menachem, Elinor
    Dominguez, Jacqueline
    Szasz, Jozsef
    Beller, Cynthia
    Howerton, Charles
    Jensen, Lori
    McClung, Carrie
    Roebling, Robert
    Steiniger-Brach, Bjorn
    [J]. EPILEPSIA OPEN, 2021, 6 (03) : 618 - 623
  • [10] Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy
    Ben-Menachem, Elinor
    Grebe, Hans Peter
    Terada, Kiyohito
    Jensen, Lori
    Li, Ting
    De Backer, Marc
    Steiniger-Brach, Bjorn
    Gasalla, Teresa
    Brock, Melissa
    Biton, Victor
    [J]. EPILEPSIA, 2019, 60 (12) : 2437 - 2447